StockData

Integra LifeSciences vs Penumbra

IART and PEN side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IART and PEN compare

Penumbra is the larger company, worth 12 times as much as Integra LifeSciences ($12.6B against $1.1B).

On earnings, Integra LifeSciences is cheaper: it trades at 79.7× trailing earnings, against 80.4× for Penumbra.

Penumbra grew revenue faster over the last twelve months (17.0% versus 0.84% for Integra LifeSciences).

Penumbra keeps more of each dollar of sales as profit, with a net margin of 10.1% compared with 0.79% at Integra LifeSciences.

Penumbra scores higher on the StockData Score (15 against 9 for Integra LifeSciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIARTPEN
Size and price
Market cap$1.1B$12.6B
Share price$13.55$319.11
Change, 1 year15.3%13.9%
Change, 5 years−79.1%27.6%
Beta (5Y)1.910.08
Employees3,7004,700
StockData Score
Total score915 (better)
Valuation score3 (better)2
Growth score23 (better)
Performance score34 (better)
Health score16 (better)
Dividend score00
Valuation
P/E79.7× (better)80.4×
P/S0.6× (better)8.1×
P/B1.0× (better)7.9×
EV/EBITDA10.2× (better)56.9×
P/FCF12.3× (better)62.8×
FCF yield8.1% (better)1.6%
Fair value$14.78$184.73
Margin of safety8.3% (better)−72.7%
Growth
Revenue growth (TTM)0.84%17.0% (better)
Revenue growth, 5Y average3.6%20.2% (better)
Net income growth (TTM)–−4.3%
EPS growth (TTM)–−4.1%
Profitability
Gross margin52.4%68.0% (better)
Operating margin4.4%12.1% (better)
Net margin0.79%10.1% (better)
FCF margin5.2%12.8% (better)
Return on equity1.2%10.7% (better)
Return on invested capital5.6%15.9% (better)
Financial health
Debt / equity–0.00
Interest coverage0.8×149× (better)
Current ratio3.625.89 (better)
Altman Z-score1.2719.09 (better)
Piotroski F-score58 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions94.4%86.6%
Held by insiders3.4%3.4%
Insider net buying, 12 months$0 (better)−$5.9M
Short interest, % of float10.5%6.3%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.